Table 3.
Clinical characteristics of immune-related encephalitis (IRE) cases
| Patient number | Clinical picture | Onset days | Brain MRI | CSF LP | CSF Protein mg\dl |
PNP AB | mRS onset | mRS outcome |
|---|---|---|---|---|---|---|---|---|
| 1 | Generalized epileptic event and speech disturbances | 20 | Normal | 27 | 55 | Negative | 4 | 1 |
| 2 | Confusional state | 12 | Normal | 15 | 90 | NT | 5 | 6 |
| 3 | Cerebellar ataxia, opsoclonus, tremor | 9 | Normal | 1 | 80 | Negative | 5 | 3 |
| 4 | Psychotic state | 24 | Normal | 1 | 54 | Negative | 4 | 0 |
| 5 | Confusional state, somnolence | 21 | Normal | 0 | 26 | NT | 3 | 1 |
| 6 | Confusional state, somnolence, headache | 210 | Normal | 75 | 98 | NT | 3 | 0 |
| 7 | Speech and behavioral disturbance, generalized and complex partial epileptic event | 110 | Abnormal | 60 | 101 | Negative | 5 | 6 |
| 8 | Confusional state and generalized epileptic event | 150 | Normal | 1 | 94 | Negative | 5 | 3 |
| 9 | Confusional state and sensory neuropathy | 15 | Normal | 3 | 166 | Negative | 4 | 0 |
| 10 | Ataxia, speech disturbances, partial seizure | 11 | Normal | 29 | 105 | Negative | 3 | 0 |
| 11 | Headache, confusional state | 15 | Normal | 6 | 59 | NT | 3 | 1 |
*Onset of symptoms in days since ICI treatment start
NT, not tested; CFS LP, lymphocytic pleocytosis tested in CSF; PNP AB, araneoplastic antibodies tested in CSF; mRS, modified Rankin Scale